BroadenBio
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing novel small molecule drugs for oncology and immunology using a proprietary discovery platform.
OncologyImmunology
Technology Platform
A proprietary integrated platform for small molecule discovery and optimization, utilizing computational chemistry and structural biology to target difficult disease pathways.
Opportunities
Significant market demand in China for novel, targeted oncology and immunology therapies presents a major growth opportunity.
Risk Factors
Clinical trial failures or unexpected toxicities in its lead programs pose the primary risk to valuation and survival.
Competitive Landscape
Faces intense competition in the crowded oncology small molecule space from both global pharma and a growing number of innovative Chinese biotechs.